It offers an exciting opportunity for investors to subscribe to the offer within the specified
period and enhance their stake in the company at a potentially attractive price.
Mumbai, 2025: Remedium Lifecare Limited (BSE: 539561) has announced the
launch of its much-anticipated Rights Issue, which has received approval from the Bombay
Stock Exchange (BSE). This strategic initiative marks a significant step in the company’s
journey toward becoming a vertically integrated, research-driven pharmaceutical leader. The
Rights Issue will open on April 30, 2025, and close on May 14, 2025.
The capital raise comes on the heels of Remedium’s recent ₹182.7 crore agreement with a
prominent UK-based pharmaceutical company, underscoring its commitment to international
expansion. The funds raised will be utilized to strengthen working capital, Investment in R&D
capabilities, scale up the production of high-value pharmaceutical intermediates, attract top
talent, drive digital transformation, and accelerate global market penetration.
Speaking on the development, Mr. Adarsh Munjal, Managing Director of Remedium Lifecare
Limited, commented: “This Rights Issue represents a significant milestone in our journey to
become a globally recognized, innovation-led pharmaceutical company. The capital infusion
will strengthen our strategic partnerships across domestic and international markets, with a
particular focus on Europe and Asia.”
He also added that “It offers an exciting opportunity for investors to subscribe to the offer
within the specified period and enhance their stake in the company at a potentially attractive
price.”
A substantial portion of the proceeds will be directed toward the establishment of advanced
research laboratories specializing in Central Nervous System (CNS) disorders, metabolic
conditions, and oncology—three of the most critical and high-demand therapeutic segments
worldwide. The capital raise will also support prepayment, improving financial resilience.
This initiative not only amplifies Remedium Lifecare’s operational and research capabilities
but also supports India’s growing reputation as a reliable pharmaceutical manufacturing and
supply chain hub. Through continued investments in high-quality infrastructure and cuttingedge
R&D, the company is aligned with the national ‘Make in India’ initiative, while
contributing to job creation and sustainable sectoral growth.
Backed by a robust growth strategy, strong global partnerships, and an expanding innovation
pipeline, Remedium Lifecare is well-positioned as an attractive opportunity for investors
seeking long-term value in India’s rapidly expanding pharmaceutical and healthcare landscape.
Key Highlights of the Rights Issue:
Closing Price: ₹ 1.79 as on 25th April 2025
Right issue price: ₹ 1 per share
Ratio: 61 Rights Equity Shares for every 50 Equity Shares held on Record Date
Record Date: Tuesday, April 15, 2025
Rights Issue Opening Date: Wednesday, 30th April 2025
Rights Issue Closing Date: Wednesday, 14th May 2025
Renunciation of Rights Entitlement Period: 30th April to 9th May 2025
Rights Issue Size: ₹ 49.19 crores
